Related Experiment Video

Updated: Sep 22, 2025

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.2K

Periplocin Alleviates Cardiac Remodeling in DOCA-Salt-Induced Heart Failure Rats

Jiameng Hao1,2, Liping Chang1,2, Dandong Wang1,2

  • 1Hebei Medical University, Shijiazhuang, 050017, Hebei, China.

Journal of Cardiovascular Translational Research
|May 26, 2022
PubMed

Insights

Periplocin shows promise in treating heart failure with preserved ejection fraction (HFpEF). This study found it improves cardiac function and reduces inflammation in rat models, suggesting potential as a new HFpEF therapy.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Biomedical Science

Background:

  • Heart failure with preserved ejection fraction (HFpEF) presents a significant public health challenge with high morbidity and mortality.
  • Current therapeutic options for HFpEF remain limited, necessitating the exploration of novel treatment strategies.

Purpose of the Study:

  • To investigate the therapeutic effects of Periplocin on a rat model of DOCA-induced heart failure.
  • To elucidate the underlying mechanisms by which Periplocin may exert its beneficial effects in HFpEF.

Main Methods:

  • Utilized a deoxycorticosterone acetate (DOCA)-induced rat model to simulate HFpEF conditions.
  • Assessed the impact of Periplocin on cardiac structure, diastolic function, and cardiomyocyte contractility.
  • Monitored inflammatory cell recruitment and serum inflammatory cytokine levels.

Main Results:

  • Periplocin significantly attenuated cardiac structural remodeling and enhanced diastolic function in the HFpEF model.
  • Treatment with Periplocin markedly inhibited inflammatory and immune cell infiltration and reduced serum inflammatory cytokine expression.
  • Periplocin demonstrated cardiac glycoside-like effects, improving cardiomyocyte contractility and calcium transient amplitude.

Conclusions:

  • Periplocin exhibits significant potential as a therapeutic agent for heart failure with preserved ejection fraction (HFpEF).
  • Its multifaceted actions, including anti-inflammatory effects and direct improvement of cardiomyocyte function, support its consideration for clinical development in HFpEF patients.

Keywords:
Cardiac remodelingHFpEFInflammationPeriplocin

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.7K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
528
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
506
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
67
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
44